AMRI first-quarter total revenue down 9 percent to $49.

We are proceeding with our previously communicated plans to employ additional scientific talent at these locations. Our two announced collaborations recently, with Navigen Pharmaceuticals and CHDI Foundation, are indications of an elevated demand for our integrated drug discovery services platform spanning both chemistry and biology services. Dr. D’Ambra continued, As we enter the next quarter, integration attempts for our new location in the United Kingdom are well underway and we continue being worked up about the prospects for this new component of our services offering. Capital and Liquidity Resources At March 31, 2010, AMRI had cash, cash equivalents and marketable securities of $84.7 million, in comparison to $111.at December 31 1 million, 2009.3 million in cash, cash equivalents and marketable securities in the first quarter of 2010 was because of the buy of Excelsyn Ltd.The exclusion of such patients may have biased our results, therefore we used multiple imputation to assign values to missing risk outcomes and factors in regression modeling. However, we did not impute data for sufferers who got no cognitive-outcomes data . We used solitary imputation for missing coma and delirium assessments. Of 10,558 patient-days during which coma or delirium assessments had been expected, only 3 percent were missing and needed imputation. Statistical Analysis To determine whether the duration of delirium and the dosages of sedative or analgesic agents were independent risk factors for the primary outcome variable , we used multiple linear regression with adjustment for most aforementioned covariates in separate models for the outcomes at 3 and 12 months.